Navigation Links
Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
Date:9/24/2008

CINCINNATI, Sept. 24 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced it has been recognized by FORTUNE magazine as one of the 100 fastest-growing companies in the United States for 2008. Kendle ranked 67th and is the only CRO to make the 2008 list.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"Kendle's recognition as one of FORTUNE magazine's 100 fastest-growing companies further reaffirms our ability to deliver value for our customers and shareholders," said Chairman and CEO Candace Kendle, PharmD. "We remain focused on our customer and business expansion strategy to position Kendle as a best-in-class drug development partner. Our talented team of associates worldwide continues to deliver an outstanding effort as we execute every day on our mission of bringing new life-saving and life-enhancing drugs to market for the benefit of patients around the world." She continued, "We look forward to driving continued future growth in our business and to leveraging the increasing strength of our global organization to capitalize on the strong demand for Phase I through IV outsourcing services."

The FORTUNE list of the 100 fastest-growing companies is based on three years of revenue and profit growth and total return using data provided by Zacks Investment Research. FORTUNE notes that Kendle's three-year annual compounded results show earnings growth of 27 percent, revenue growth of 44 percent and a total return of 34 percent. Kendle is on track to deliver continued strong growth this fiscal year, with earnings per share projected to increase by 59 to 71 percent over reported GAAP earnings of $1.26 per share for fiscal 2007.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com .

Certain statements contained in this press release may be deemed to be forward looking statements under the U.S. federal securities laws, including the Private Securities Litigation Reform Act of 1995, and Kendle intends that such forward-looking statements be subject to the safe-harbor provisions created thereby. Such forward looking statements include Zack's Investment Research statements regarding Kendle's growth, profitability and expected earnings per share. Kendle cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained herein. Such factors include: (a) changes in the markets for the company's products and services; (b) the company's ability to penetrate new markets; (c) the successful integration of the company's various acquisitions; (d) changes in the market for customers' products; (e) the ability of Kendle's management, individually or collectively, to guide the company in a successful manner; (f) competitive factors and industry consolidation, outsourcing trends in the pharmaceutical and biotechnology industry; (g) the effects of exchange rate fluctuations and risks related to the company's non-U.S. operations; and (h) other risks as detailed from time to time in Kendle's SEC reports, including its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Annual Reports on Form 10-K. All information in this release is current as of September 24, 2008. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the UBS Global Life Sciences Conference
2. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
3. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
4. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
5. Kendle Appoints Patricia Williams Vice President, Commercial Operations
6. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
7. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. Kendle Leaders Adopt 10b5-1 Trading Plans
9. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
10. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
11. Kendle to Present at the Wachovia 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... PA (PRWEB) , ... January 18, 2017 , ... ... operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency ... engaging panel discussions to examine vital clinical research issues such as trial performance ...
(Date:1/18/2017)... ... ... Thirty-six startup companies in University City and Center City have been awarded ... Development in 2016 as part of the Keystone Innovation Zone (KIZ) Tax Credit Program. ... represent the highest number of awards to the largest number of companies in the ...
(Date:1/18/2017)... Jan. 18, 2017  Caris Life Sciences, a ... Foundation, the largest private funder of pancreatic cancer ... evaluating the impact of immunotherapy in the treatment ... enrollment services to identify potential trial candidates based ... treating physicians and study investigators. The Lustgarten Foundation ...
(Date:1/17/2017)... ... January 17, 2017 , ... LGC Maine ... its VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® SP2 evaluates Albumin, ... VALIDATE® SP2 kit is prepared using the CLSI recommended “equal delta” method for ...
Breaking Biology Technology:
(Date:1/13/2017)... N.Y. , Jan. 13, 2017 ... technology solutions for the homecare industry, including Electronic ... homecare industry expert, Justin Jugs, as Senior Vice ... more than 15 years of homecare experience to ... in developing strategic plans to align Sandata,s suite ...
(Date:1/12/2017)... PORTLAND, Oregon and PUNE, India , January 12, 2017 ... Technology Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology ... CAGR of 19.4% from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
Breaking Biology News(10 mins):